Published in Cancer J on April 20, 2010
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol (2005) 8.08
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol (2007) 3.85
Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol (2007) 2.53
Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol (2009) 2.50
(124)I-huA33 antibody PET of colorectal cancer. J Nucl Med (2011) 2.01
Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol (2005) 1.92
Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann Surg (2008) 1.85
Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biol (2014) 1.76
Overexpression of E2F-1 in lung and liver metastases of human colon cancer is associated with gene amplification. Cancer Biol Ther (2004) 1.67
Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer. Ann Surg (2011) 1.57
Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease. Ann Surg Oncol (2002) 1.50
Hepatic arterial infusion after liver resection. N Engl J Med (2005) 1.44
Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases. J Am Coll Surg (2007) 1.39
Effect of postoperative morbidity on long-term survival after hepatic resection for metastatic colorectal cancer. Ann Surg (2008) 1.39
BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer (2014) 1.32
Margin size is an independent predictor of local tumor progression after ablation of colon cancer liver metastases. Cardiovasc Intervent Radiol (2012) 1.29
Role of adjuvant therapy after resection of colorectal cancer liver metastases. J Clin Oncol (2010) 1.20
Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. J Clin Oncol (2003) 1.12
Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581. J Clin Oncol (2011) 1.12
124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET. J Nucl Med (2011) 1.08
Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy. Cancer (2010) 1.07
High-grade neuroendocrine carcinoma of the colon, long-term survival in advanced disease. Med Oncol (2010) 1.06
Phase I study of anticolon cancer humanized antibody A33. Clin Cancer Res (2003) 1.04
Treatment of pulmonary colorectal metastases by radiofrequency ablation. Clin Colorectal Cancer (2012) 1.03
An update on hepatic arterial infusion chemotherapy for colorectal cancer. Oncologist (2003) 1.03
Treatment of metastatic colon cancer: "the times they are A-changing". J Clin Oncol (2013) 1.02
Role of intra-arterial hepatic chemotherapy in the treatment of colorectal cancer metastases. J Surg Oncol (2010) 1.02
Preliminary report of a phase I study of combination chemotherapy and humanized A33 antibody immunotherapy in patients with advanced colorectal cancer. Clin Cancer Res (2003) 1.02
Chemotherapy for the conversion of unresectable colorectal cancer liver metastases to resection. Crit Rev Oncol Hematol (2010) 1.00
Ki-67 is a prognostic biomarker of survival after radiofrequency ablation of liver malignancies. Ann Surg Oncol (2012) 0.99
Pathologic response to preoperative chemotherapy in colorectal liver metastases: fibrosis, not necrosis, predicts outcome. Ann Surg Oncol (2012) 0.99
Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials. Ann Surg Oncol (2014) 0.96
CT-guided radiofrequency ablation as a salvage treatment of colorectal cancer hepatic metastases developing after hepatectomy. J Vasc Interv Radiol (2011) 0.96
The role of floxuridine in metastatic liver disease. Mol Cancer Ther (2009) 0.95
Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement. Cancer (2010) 0.95
Regional chemotherapy for liver-limited metastatic colorectal cancer. Clin Colorectal Cancer (2008) 0.93
Intrahepatic arterial infusion of chemotherapy: clinical results. Semin Oncol (2002) 0.87
Assessing the optimal duration of chemotherapy in patients with colorectal liver metastases. J Surg Oncol (2008) 0.86
Biliary sclerosis after hepatic arterial infusion pump chemotherapy for patients with colorectal cancer liver metastasis: incidence, clinical features, and risk factors. Ann Surg Oncol (2011) 0.86
Conversion to complete resection and/or ablation using hepatic artery infusional chemotherapy in patients with unresectable liver metastases from colorectal cancer: a decade of experience at a single institution. Ann Surg Oncol (2013) 0.83
Treatment of extensive metastatic colorectal cancer to the liver with systemic and hepatic arterial infusion chemotherapy and two-stage hepatic resection: the role of salvage therapy for recurrent disease. Ann Surg Oncol (2013) 0.82
Current strategies using hepatic arterial infusion chemotherapy for the treatment of colorectal cancer. Clin Colorectal Cancer (2005) 0.81
Patterns of failure in patients with early onset (synchronous) resectable liver metastases from rectal cancer. Cancer (2012) 0.80
Nasal septum perforation and bevacizumab. Med Oncol (2010) 0.80
Safety and efficacy of panitumumab following cetuximab: retrospective review of the Memorial Sloan-Kettering experience. Invest New Drugs (2009) 0.80
A case report of a patient with advanced acinar cell carcinoma of the pancreas: long-term survival with regional, systemic and targeted therapy. Tumori (2013) 0.79
Floxuridine hepatic arterial infusion associated biliary toxicity is increased by concurrent administration of systemic bevacizumab. Ann Surg Oncol (2013) 0.79
Recurrence After Partial Hepatectomy for Metastatic Colorectal Cancer: Potentially Curative Role of Salvage Repeat Resection. Ann Surg Oncol (2015) 0.79
PET-based compartmental modeling of (124)I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer. Eur J Nucl Med Mol Imaging (2015) 0.79
Advances in neoadjuvant therapy for colorectal cancer with liver metastases. Cancer Treat Rev (2008) 0.78
Regional hepatic chemotherapies in treatment of colorectal cancer metastases to the liver. Semin Oncol (2010) 0.77
Angiographic identification of extrahepatic perfusion after hepatic arterial pump placement: implications for surgical prevention. HPB (Oxford) (2013) 0.75
Long-term outcome of unresectable metastatic colorectal cancer: does "adjuvant" chemotherapy play a role after resection? Ann Surg (2009) 0.75
Colorectal hepatic metastases: adjuvant chemotherapy and survival. J Clin Oncol (2009) 0.75
Serial measurement of hepatic lipids during chemotherapy in patients with colorectal cancer: a 1 H MRS study. NMR Biomed (2012) 0.75
Changing paradigms for liver resection of colorectal metastases. Ann Surg Oncol (2012) 0.75
Systemic or regional chemotherapy for liver metastases from colorectal cancer: has the wheel stopped spinning? Cancer J (2004) 0.75
The adrenal gland: fascinating, but still many advances to be made. J Surg Oncol (2012) 0.75
Continued survival of more than ten years, without resection of metastatic disease, in patients with metastatic colorectal cancer treated with biomodulated fluorouracil: report of two cases. Dis Colon Rectum (2006) 0.75
Metastases to the breast from primary pancreatic cancer. Breast J (2005) 0.75
Metastatic Colorectal Cancer to the Liver: Involve the Surgeon Early and Often. Ann Surg Oncol (2015) 0.75
Hepatic artery infusional chemotherapy in patients with unresectable colorectal liver metastases and extrahepatic disease. J Surg Oncol (2012) 0.75
Persistent CEA elevation in a patient with psoriasis and a history of metastatic colorectal cancer with no evidence of residual tumor. Dig Dis Sci (2004) 0.75